Literature DB >> 32242182

A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).

Hari Talreja1, Jasmine Tan2, Matt Dawes3, Sharen Supershad4, Kannaiyan Rabindranath5, James Fisher6, Sajed Valappil2, Veronica van der Merwe7, Lisa Wong8, Walter van der Merwe9, Julian Paton10.   

Abstract

There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes. We reviewed the available evidence, and have not found this to be the case. We recommend that patients on such medications should continue on them unless there is a clinical indication to stop their use.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32242182

Source DB:  PubMed          Journal:  N Z Med J        ISSN： 0028-8446


  9 in total

1.  Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19.

Authors:  Sikandar Hayat Khan; Sabeen Khurshid Zaidi
Journal:  Drugs Ther Perspect       Date:  2020-06-09

Review 2.  Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence.

Authors:  Celestino Sardu; Jessica Gambardella; Marco Bruno Morelli; Xujun Wang; Raffaele Marfella; Gaetano Santulli
Journal:  J Clin Med       Date:  2020-05-11       Impact factor: 4.241

Review 3.  COVID-19: A Concern for Cardiovascular Disease Patients.

Authors:  Shruti Sharma
Journal:  Cardiovasc Toxicol       Date:  2020-07-29       Impact factor: 3.231

Review 4.  Human cell receptors: potential drug targets to combat COVID-19.

Authors:  Pawan Kumar Raghav; Keerthana Kalyanaraman; Dinesh Kumar
Journal:  Amino Acids       Date:  2021-05-05       Impact factor: 3.520

Review 5.  Recent advances in developing small-molecule inhibitors against SARS-CoV-2.

Authors:  Rong Xiang; Zhengsen Yu; Yang Wang; Lili Wang; Shanshan Huo; Yanbai Li; Ruiying Liang; Qinghong Hao; Tianlei Ying; Yaning Gao; Fei Yu; Shibo Jiang
Journal:  Acta Pharm Sin B       Date:  2021-07-02       Impact factor: 14.903

Review 6.  Type-2 Diabetes as a Risk Factor for Severe COVID-19 Infection.

Authors:  Mahnaz Norouzi; Shaghayegh Norouzi; Alistaire Ruggiero; Mohammad S Khan; Stephen Myers; Kylie Kavanagh; Ravichandra Vemuri
Journal:  Microorganisms       Date:  2021-06-03

7.  Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.

Authors:  Alberto Palazzuoli; Massimo Mancone; Gaetano M De Ferrari; Giovanni Forleo; Gioel G Secco; Gaetano M Ruocco; Fabrizio D'Ascenzo; Silvia Monticone; Anita Paggi; Marco Vicenzi; Anna G Palazzo; Maurizio Landolina; Erika Taravelli; Guido Tavazzi; Francesco Blasi; Fabio Infusino; Francesco Fedele; Francesco G De Rosa; Michael Emmett; Jeffrey M Schussler; Kristen M Tecson; Peter A McCullough
Journal:  J Am Heart Assoc       Date:  2020-10-07       Impact factor: 5.501

Review 8.  Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin.

Authors:  Hakan Parlakpinar; Seyhan Polat; Haci Ahmet Acet
Journal:  Fundam Clin Pharmacol       Date:  2020-10-14       Impact factor: 2.747

9.  Risk of Acquiring Perioperative COVID-19 During the Initial Pandemic Peak: A Retrospective Cohort Study.

Authors:  Lucas G Axiotakis; Brett E Youngerman; Randy K Casals; Tyler S Cooke; Graham M Winston; Cory L Chang; Deborah M Boyett; Anil K Lalwani; Guy M McKhann
Journal:  Ann Surg       Date:  2021-01-01       Impact factor: 13.787
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.